R&D | January 16, 2026
Redesigned brain receptor drugs show promise for depression
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
The BD Neopak Glass Prefillable Syringe platform is designed for the complex needs of biologics and combination products
Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement
Subscribe To Our Newsletter & Stay Updated
